International Stem Cell CORP
Close on Oct 19, 2026
- Market cap
- $2.27M
- P/E (TTM)
- –
- Dividend yield
- –
About International Stem Cell
Pharmaceutical Preparations, SIC 2834
International Stem Cell Corporation is a clinical-stage biotechnology company that focuses on developing therapeutic and biomedical products using human parthenogenetic stem cells. The company develops neural stem cells for central nervous system disorders such as Parkinson's disease, traumatic brain injury, and stroke. In addition to clinical research, it operates two commercial business units: research products and anti-aging skincare. Its research subsidiary manufactures human cell culture products, primary cells, stem cells, and specialized media for pharmaceutical, academic, and government research scientists. Its skincare subsidiary offers anti-aging cosmetic products to consumers and professionals, including dermatologists and plastic surgeons.
The company operates a research and development facility in San Diego, California, and a cGMP manufacturing facility in Frederick, Maryland. It also maintains a research subsidiary in Victoria, Australia, which conducts clinical trials. Products are distributed domestically and internationally across Europe and Asia. The company's corporate headquarters are located in San Diego, California.
Summary of the business section of International Stem Cell's latest annual report, written by StockData.
Company profile
Company
- Legal name
- International Stem Cell CORP
- Headquarters
- San Diego, CA
- Address
- 9745 Businesspark Avenue 92131
- Phone
- (760) 940-6383
- Website
- internationalstemcell.com
- Employees
- 33, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., San Diego, California
Stock & identifiers
- Ticker
- ISCO
- Exchange
- OTC
- IPO date
- Jan 22, 2008
- Shares outstanding
- 8M, Aug 11, 2026
- Public float
- $592.08K, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-150 reverse, Jul 29, 2015; 1-for-150 reverse, Jul 29, 2015
- SEC CIK
- 1355790
- EIN
- 20-4494098
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul V. Maier | Director | 31,710 |
| Wright Don | Director | 4,739 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Andrey Semechkin | $88.54K | $136.47K | $370.00K | $175 | – |
| FY2024 Dr. Andrey Semechkin | $66.48K | $142.55K | $260.00K | $133 | – |
| FY2023 Dr. Andrey Semechkin | $112.87K | $81.57K | $377.24K | $33 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“At December 31, 2025, including our 2 executive officers, we had 33 full-time employees.”
Corporate history
Events identified from SEC filings